Drug intelligence / Profile preview

GA-2601

Development stage: Preclinical
Lead developer: Galt Pharmaceuticals

Overview

GA-2601 is a preclinical-stage drug candidate being developed by Galt Pharmaceuticals for the treatment of migraine. As of 2024, the compound is in the early research and development phase. Specific details regarding its chemical structure, modality (e.g., small molecule vs. biologic), and biological target have not been publicly disclosed by the sponsor. The asset is part of Galt's early-stage pipeline alongside other candidates like GA-2701.

Beyond the preview

Go deeper on GA-2601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GA-2601.

Explore the full profile